Resonance Health (ASX:RHT) FCF Margin % : 26.80% (As of Jun. 2024)

View and export this data going back to 1987. Start your Free Trial

What is Resonance Health FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Resonance Health's Free Cash Flow for the six months ended in Jun. 2024 was A$1.43 Mil. Resonance Health's Revenue for the six months ended in Jun. 2024 was A$5.32 Mil. Therefore, Resonance Health's FCF Margin % for the quarter that ended in Jun. 2024 was 26.80%.

As of today, Resonance Health's current FCF Yield % is 3.49%.

The historical rank and industry rank for Resonance Health's FCF Margin % or its related term are showing as below:

ASX:RHT' s FCF Margin % Range Over the Past 10 Years
Min: -56.4 Med: -2.39 Max: 34.95
Current: 11.76

During the past 13 years, the highest FCF Margin % of Resonance Health was 34.95%. The lowest was -56.40%. And the median was -2.39%.

ASX:RHT's FCF Margin % is ranked better than
80.36% of 672 companies
in the Healthcare Providers & Services industry
Industry Median: 2.39 vs ASX:RHT: 11.76

Resonance Health FCF Margin % Historical Data

The historical data trend for Resonance Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resonance Health FCF Margin % Chart

Resonance Health Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

28.90

20.46

-56.40

-14.19

11.76

Resonance Health Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial															-58.25	-16.90	-11.72	-12.77	26.80

Competitive Comparison of Resonance Health's FCF Margin %

For the Health Information Services subindustry, Resonance Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resonance Health's FCF Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Resonance Health's FCF Margin % falls into.

Resonance Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Resonance Health's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	1.01	/	8.589
	=	11.76 %

Resonance Health's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	1.427	/	5.324
	=	26.80 %

Resonance Health FCF Margin % Related Terms

Thank you for viewing the detailed overview of Resonance Health's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Resonance Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Resonance Health Ltd (ASX:RHT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

141-143 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100

Website

https://www.resonancehealth.com

Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, Cardiac T2, and HepaFat-Scan. It also has several AI-assisted SaMDs including FerriSmart, HepaFat-AI, and LiverSmart. The company's business segments are; Services which derives key revenue, Research and development, Corporate, Clinical Research Organization (CRO), and TrialsWest. Geographically, it generates maximum revenue from the Asia Pacific and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.

Resonance Health Headlines

No Headlines